Table 4.
Time-dependent AUCs and Brier Scores of the Different Survival Models.
| Model | Time (y) | AUC | Brier Score |
|---|---|---|---|
| 17 genes (PC1 + PC2 + PC3 + PC4) | 0.5 | 65.11 | 0, 063 |
| 17 genes (PC1 + PC2 + PC3 + PC4) | 1 | 69.12 | 0, 113 |
| 17 genes (PC1 + PC2 + PC3 + PC4) | 2 | 69.79 | 0, 142 |
| 17 genes (PC1 + PC2 + PC3 + PC4) | 5 | 67.21 | 0, 183 |
| COO + MHG | 0.5 | 52.78 | 0, 066 |
| COO + MHG | 1 | 60.69 | 0, 119 |
| COO + MHG | 2 | 64.14 | 0, 150 |
| COO + MHG | 5 | 63.27 | 0, 190 |
| IPI score | 0.5 | 74.70 | 0, 061 |
| IPI score | 1 | 74.27 | 0, 109 |
| IPI score | 2 | 74.57 | 0, 136 |
| IPI score | 5 | 72.83 | 0, 173 |
| IPI score + 17 genes (PC1 + PC2 + PC3 + PC4) | 0.5 | 74.56 | 0, 058 |
| IPI score + 17 genes (PC1 + PC2 + PC3 + PC4) | 1 | 77.48 | 0, 101 |
| IPI score + 17 genes (PC1 + PC2 + PC3 + PC4) | 2 | 78.73 | 0, 124 |
| IPI score + 17 genes (PC1 + PC2 + PC3 + PC4) | 5 | 76.45 | 0, 160 |
| IPI score + COO + MHG | 0.5 | 70.38 | 0, 062 |
| IPI score + COO + MHG | 1 | 74.11 | 0, 107 |
| IPI score + COO + MHG | 2 | 76.98 | 0, 130 |
| IPI score + COO + MHG | 5 | 75.95 | 0, 162 |
| IPI score + COO + MHG + 17 genes (PC1 + PC2 + PC3 + PC4) | 0.5 | 72.05 | 0, 059 |
| IPI score + COO + MHG + 17 genes (PC1 + PC2 + PC3 + PC4) | 1 | 75.91 | 0, 102 |
| IPI score + COO + MHG + 17 genes (PC1 + PC2 + PC3 + PC4) | 2 | 78.57 | 0, 124 |
| IPI score + COO + MHG + 17 genes (PC1 + PC2 + PC3 + PC4) | 5 | 76.96 | 0, 160 |
Evaluated time points were 6 mo and 1, 2, and 5 y after diagnosis. Results were obtained from the whole cohort of DLBCL patients treated with R-CHOP (N = 481).
AUC = area under the curve; COO = cell-of-origin; DLBCL = diffuse large B-cell lymphoma; IPI = International Prognostic Index; MHG = molecular high-grade; PC = principal component; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.